Psychosis - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 65 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Psychosis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Psychosis - Pipeline Review, H2 2014', provides an overview of the Psychosis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Psychosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Psychosis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Psychosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Psychosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Psychosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Psychosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Psychosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Psychosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Psychosis Overview 7
Therapeutics Development 8
Pipeline Products for Psychosis - Overview 8
Pipeline Products for Psychosis - Comparative Analysis 9
Psychosis - Therapeutics under Development by Companies 10
Psychosis - Therapeutics under Investigation by Universities/Institutes 12
Psychosis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Psychosis - Products under Development by Companies 17
Psychosis - Products under Investigation by Universities/Institutes 18
Psychosis - Companies Involved in Therapeutics Development 19
Eli Lilly and Company 19
Sumitomo Dainippon Pharma Co., Ltd. 20
Addex Therapeutics Ltd 21
Evotec AG 22
Acadia Pharmaceuticals Inc. 23
Newron Pharmaceuticals S.p.A. 24
Adamas Pharmaceuticals, Inc. 25
Heptares Therapeutics Ltd. 26
Clera Inc. 27
Reviva Pharmaceuticals Inc. 28
Psychosis - Therapeutics Assessment 29
Assessment by Monotherapy Products 29
Assessment by Target 30
Assessment by Mechanism of Action 33
Assessment by Route of Administration 36
Assessment by Molecule Type 37
Drug Profiles 38
pimavanserin tartrate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
LY-404039 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Small Molecule to Inhibit PDE10a for Schizophrenia and Psychosis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
NW-3509 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CLR-100 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
ADX-71743 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Drug to Agonize Muscarinic M1/M4 Receptors for CNS Disorders - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecules to Agonize M1/M4 Muscarinic Acetylcholine Receptors for Psychosis - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CLR-136 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Small Molecule to Activate Sigma Receptor for CNS Disorders - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
ADS-8800 Series - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
RP-5063 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Psychosis - Recent Pipeline Updates 52
Psychosis - Dormant Projects 57
Psychosis - Discontinued Products 58
Psychosis - Product Development Milestones 59
Featured News & Press Releases 59
Mar 17, 2014: Ameritox Launches New Method to Help Assess Medication Non-Adherence for Patients Prescribed Top-Selling Drug Abilify 59
Nov 13, 2012: AstraZeneca Announces German Federal Patent Court Invalidates Seroquel XR Formulation Patent 60
Aug 30, 2012: Janssen Pharma To Pay $181m For Settlement Of Improper Marketing Claims For Antipsychotic Drugs 60
Apr 19, 2010: Mylan Launches Clozapine Tablets USP, 50mg And 200mg In US 61
Apr 14, 2010: Joseph Friedman To Present Data From ACADIA's First Phase III Trial With Pimavanserin For PDP At 62nd American Academy Of Neurology Annual Meeting 61
Sep 01, 2009: ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis 62
May 06, 2009: ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 63
Jun 11, 2007: ACADIA Pharmaceuticals Initiates Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis 63
Appendix 64
Methodology 64
Coverage 64
Secondary Research 64
Primary Research 64
Expert Panel Validation 64
Contact Us 65
Disclaimer 65

List of Tables
Number of Products under Development for Psychosis, H2 2014 8
Number of Products under Development for Psychosis - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Comparative Analysis by Unknown Stage Development, H2 2014 16
Products under Development by Companies, H2 2014 17
Products under Investigation by Universities/Institutes, H2 2014 18
Psychosis - Pipeline by Eli Lilly and Company, H2 2014 19
Psychosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2014 20
Psychosis - Pipeline by Addex Therapeutics Ltd, H2 2014 21
Psychosis - Pipeline by Evotec AG, H2 2014 22
Psychosis - Pipeline by Acadia Pharmaceuticals Inc., H2 2014 23
Psychosis - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 24
Psychosis - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 25
Psychosis - Pipeline by Heptares Therapeutics Ltd., H2 2014 26
Psychosis - Pipeline by Clera Inc., H2 2014 27
Psychosis - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 28
Assessment by Monotherapy Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 32
Number of Products by Stage and Mechanism of Action, H2 2014 35
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 37
Psychosis Therapeutics - Recent Pipeline Updates, H2 2014 52
Psychosis - Dormant Projects, H2 2014 57
Psychosis - Discontinued Products, H2 2014 58